Auxilium Pharmaceuticals

Auxilium touts top-line data from Xiaflex study in Dupuytren's contracture

Monday, July 30, 2012 11:34 AM

Auxilium Pharmaceuticals, a specialty biopharmaceutical company based in Malvern, Penn., issued positive top-line data from its phase IIIb trial evaluating Xiaflex for the treatment of adult Dupuytren's contracture patients with multiple palpable cords. 

More... »

Auxilium and GSK to co-promote Testim in U.S.

Monday, May 21, 2012 12:35 PM

Auxilium Pharmaceuticals, a specialty biopharmaceutical company based in Malvern, Penn., and GlaxoSmithKline LLC, the U.S. subsidiary of GlaxoSmithKline plc, have entered into an agreement for the co-promotion of Auxilium’s Testim 1% (testosterone gel), which is indicated for testosterone replacement therapy in adult males for conditions associated with a deficiency or absence of testosterone.

More... »

Auxilium and Actelion collaborate for Xiaflex

Monday, February 27, 2012 09:53 AM

Auxilium Pharmaceuticals, a specialty biopharmaceutical company, and Actelion Pharmaceuticals have entered into a long-term partnership for the development, supply and commercialization of Xiaflex(collagenase clostridium histolyticum), a novel, first-in-class biologic for the potential treatment of Dupuytren's contracture and Peyronie's disease.

More... »

Auxilium doses first patients in phase Ib cellulite study

Friday, January 27, 2012 02:10 PM

Auxilium Pharmaceuticals, a specialty biopharmaceutical company, said the first cohort of patients has been dosed in its phase Ib trial of Xiaflex (collagenase clostridium histolyticum) for the treatment of edematous fibrosclerotic panniculopathy (EFP), commonly known as cellulite.

More... »

Adams joins Auxilium Pharmaceuticals

Thursday, December 8, 2011 11:56 AM

Auxilium Pharmaceuticals has named Adrian Adams chief executive officer and president, effective immediately. Adams succeeds Armando Anido, who has agreed to step down as chief executive officer and president and has resigned as a member of the board of directors.

More... »

Auxilium names Tursi chief medical officer

Tuesday, August 16, 2011 10:07 AM

Auxilium Pharmaceuticals has promoted Dr. James P. Tursi to chief medical officer. Tursi will report to Armando Anido, chief executive officer and president of Auxilium, and sit on the Auxilium Executive Committee in this role.

More... »

Auxilium releases CORDLESS results

Friday, July 1, 2011 10:24 AM

Auxilium Pharmaceuticals has announced three-year recurrence data from the Collagenase Optimal Reduction of Dupuytren's—Long-term Evaluation of Success Study (CORDLESS) for XIAFLEXR (collagenase clostridium histolyticum) in the treatment of adult Dupuytren's contracture patients with a palpable cord.

More... »

Xiapex approved for use in Europe

Monday, March 7, 2011 07:31 AM

Xiapex (collagenase clostridium histolyticum), a non-surgical treatment for Dupuytren’s contracture in adult patients with a palpable cord, has been granted marketing authorization by the European Commission and should available for use in some European markets later this year. 

More... »